Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Conference Investment Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology
SAN JOSE, Calif. , Jan. 29, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the 2024 NeauxCancer Conference organized by the Cancer Advocacy Group of Louisiana (CAGLA), being held February 29 – March 2, 2024 in New Orleans. Anixa Chairman and CEO Dr. Amit Kumar will present and meet one-on-one with investors throughout the day on Friday, March 1st.
Related news for (ANIX)
- Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences’ Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
- Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
- Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
- Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology